What is the appropriate follow‑up and monitoring plan after switching this patient to losartan 100 mg/hydrochlorothiazide 25 mg daily while continuing nifedipine extended‑release 69 mg daily and referring her to cardiology?

Follow-Up and Monitoring Plan After Switching to Losartan/HCTZ with Continued Nifedipine ER

Monitor blood pressure, renal function (serum creatinine), and serum potassium within 1–2 weeks of initiating losartan/HCTZ, then reassess blood pressure control at 4 weeks with ongoing monitoring every 3 months once stable. 1, 2

Immediate Follow-Up (1–2 Weeks Post-Initiation)

Laboratory Monitoring

• Check serum creatinine and estimated glomerular filtration rate (eGFR) – ARBs and diuretics can both affect renal function, particularly in patients with underlying chronic kidney disease or volume depletion. 1, 2, 3
• Measure serum potassium – losartan increases the risk of hyperkalemia, especially when combined with thiazide diuretics in patients with reduced renal function or those on potassium supplements or potassium-sparing agents. 1, 2, 3
• Assess volume status – hydrochlorothiazide 25 mg can cause intravascular volume depletion; monitor for orthostatic hypotension, dizziness, or signs of dehydration. 4, 5

Blood Pressure Assessment

• Obtain office blood pressure measurement – verify that the combination is not causing excessive hypotension, particularly given the concurrent use of nifedipine ER 69 mg (a high dose of a calcium channel blocker). 1, 2
• Screen for symptomatic hypotension – ask about lightheadedness, dizziness, or syncope, which may indicate excessive blood pressure lowering with triple therapy (ARB + diuretic + CCB). 1, 6

---

Short-Term Follow-Up (4 Weeks Post-Initiation)

Blood Pressure Control

• Reassess office blood pressure – the goal is <130/80 mm Hg for most patients with hypertension, or <140/90 mm Hg in older adults depending on comorbidities. 1, 2
• Consider home blood pressure monitoring or 24-hour ambulatory blood pressure monitoring (ABPM) – this is particularly useful for detecting morning hypertension, which is an independent cardiovascular risk factor and may persist despite office blood pressure control. 7, 8
• Evaluate for morning hypertension – losartan/HCTZ 100/25 mg has been shown to be highly effective for isolated morning hypertension (morning BP ≥135/85 mm Hg with evening BP <135/85 mm Hg), achieving control in 81.8% of patients versus 21.4% with losartan 100 mg alone. 8

Dose Titration

• If blood pressure remains uncontrolled (≥130/80 mm Hg or above individualized target), consider uptitrating nifedipine ER to a maximum of 90–120 mg daily (depending on formulation) or adding a fourth agent such as spironolactone 25 mg daily if the patient meets criteria for resistant hypertension. 1, 2, 9
• If blood pressure is excessively low (<110/70 mm Hg with symptoms), consider reducing the dose of one agent, typically the diuretic or calcium channel blocker. 1

---

Long-Term Monitoring (Every 3 Months Once Stable)

Ongoing Laboratory Surveillance

• Recheck serum creatinine, eGFR, and potassium every 3 months – this is critical because losartan can cause a modest rise in creatinine (acceptable if <30% increase from baseline) and hyperkalemia, particularly in patients with chronic kidney disease. 1, 2, 3
• Monitor for hypokalemia – although losartan has potassium-sparing effects, hydrochlorothiazide 25 mg can cause hypokalemia, which increases the risk of ventricular arrhythmias and sudden cardiac death, particularly if potassium falls below 3.5 mmol/L. 5
• Assess uric acid levels if clinically indicated – thiazide diuretics increase serum uric acid, though gout is uncommon at doses ≤25 mg of HCTZ. 5
• Screen for metabolic effects – thiazide diuretics can worsen glucose control and increase the incidence of new-onset diabetes, though this has not been shown to increase cardiovascular events in clinical trials. 5

Blood Pressure Monitoring

• Office blood pressure every 3 months – once blood pressure is stable and at goal, continue routine monitoring to ensure sustained control. 1, 2
• Home blood pressure monitoring – encourage the patient to check blood pressure at home, particularly in the morning, as this regimen is highly effective for morning hypertension. 7, 8

Adverse Event Surveillance

• Monitor for angioedema – although rare (<1% incidence), ARBs can cause angioedema, particularly in patients with a history of ACE inhibitor–induced angioedema. If angioedema occurs, discontinue losartan immediately and do not rechallenge. 3
• Assess for peripheral edema – nifedipine ER at 69 mg daily is associated with dose-dependent peripheral edema (approximately 19% at 90 mg daily). This is a localized vasodilatory effect and not due to heart failure, but it can be bothersome and may require dose reduction or discontinuation. 6, 10, 11
• Screen for dizziness, headache, and flushing – these are common side effects of nifedipine ER and may worsen with the addition of losartan/HCTZ due to additive vasodilation. 6
• Evaluate for sexual dysfunction – thiazide diuretics, particularly at higher doses, have been associated with erectile dysfunction, though this is less common at doses ≤25 mg of HCTZ. 5

---

Cardiology Referral Coordination

Timing of Referral

• Refer to cardiology promptly – the patient should be seen by cardiology within 4–6 weeks to evaluate for underlying cardiovascular disease (e.g., coronary artery disease, left ventricular hypertrophy, heart failure) and to optimize long-term management. 12, 1

Information to Provide to Cardiology

• Current medication regimen – losartan/HCTZ 100/25 mg daily and nifedipine ER 69 mg daily. 13, 6
• Baseline and follow-up blood pressure readings – include office, home, and ambulatory blood pressure measurements if available. 1, 2
• Laboratory results – serum creatinine, eGFR, potassium, glucose, and lipid panel. 1, 2
• Cardiovascular risk factors – document diabetes, smoking, dyslipidemia, family history of premature cardiovascular disease, and any symptoms of angina, heart failure, or peripheral arterial disease. 1, 2

---

Common Pitfalls to Avoid

• Do not assume blood pressure control based on office readings alone – morning hypertension is an independent cardiovascular risk factor and may be missed without home or ambulatory monitoring. 7, 8
• Do not overlook hyperkalemia – losartan increases potassium, and even though HCTZ lowers potassium, the net effect can still be hyperkalemia, particularly in patients with chronic kidney disease (eGFR <45 mL/min/1.73 m²). 1, 2, 3
• Do not ignore peripheral edema – nifedipine ER at high doses (69 mg) is associated with significant pedal edema, which is often bothersome to patients and may lead to nonadherence. Consider dose reduction or switching to an alternative agent if edema is problematic. 6, 10, 11
• Do not combine losartan with an ACE inhibitor – this combination increases adverse events (hyperkalemia, acute kidney injury, hypotension) without improving cardiovascular outcomes and is contraindicated. 1, 2, 3
• Do not abruptly discontinue nifedipine ER – although less common than with short-acting dihydropyridines, abrupt cessation of calcium channel blockers can cause rebound hypertension. 1